NCT00996723

Clinical Trial Evaluating the Combination of Vandetanib and Dasatinib During and After Radiation Therapy (RT) in Children With Newly Diagnosed Diffuse Intrinsic Pontine Glioma (DIPG)

Phase I Study of the Combination of Vandetanib and Dasatinib Administered During and After Radiation Therapy in Children With Diffuse Intrinsic Pontine Glioma

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 25 (actual)
• Sponsor: St. Jude Children's Research Hospital · Academic / Other
• Sex: All
• Age: 18 Months – 21 Years
• Healthy volunteers: Not accepted

Summary

This is a Phase I clinical trial evaluating the combination of vandetanib and dasatinib during and after radiation therapy (RT) in children with newly diagnosed diffuse intrinsic pontine glioma (DIPG).

Detailed description

This trial will estimate the maximum safe dose of vandetanib and dasatinib which can be administered during the 6 weeks of local RT in children with newly diagnosed DIPG.

Conditions

• Diffuse Intrinsic Pontine Glioma

Interventions

Type	Name	Description
DRUG	vandetanib and dasatinib	Two oral investigational agents (vandetanib \[VEGFR2, RET, and EGFR inhibitor\] and dasatinib \[bcr-abl, PDGFRA and B, src, lck, yes, and c-kit inhibitor\] will be administered during and after local RT, which is the only standard therapy for children with DIPG.

Timeline

• Start date: 2009-10-01
• Primary completion: 2012-04-01
• Completion: 2014-06-01
• First posted: 2009-10-16
• Last updated: 2015-04-06

Locations

1 site across 1 country: United States